Li Xian et al.
BMC nephrology, 20(1), 332-332 (2019-08-25)
Thrombospondin type 1 domain containing 7A (THSD7A) was recently identified target autoantigen in membranous nephropathy (MN). However, patients with positive THSD7A expression were prone to have malignancies. THSD7A was found to be expressed in a variety of malignant tumors. In...
Nicola M Tomas et al.
The New England journal of medicine, 371(24), 2277-2287 (2014-11-14)
Idiopathic membranous nephropathy is an autoimmune disease. In approximately 70% of patients, it is associated with autoantibodies against the phospholipase A2 receptor 1 (PLA2R1). Antigenic targets in the remaining patients are unknown. Using Western blotting, we screened serum samples from...
Autoantigens PLA2R and THSD7A in membranous nephropathy share a common epitope motif in the N-terminal domain.
Fresquet, et al.
Journal of Autoimmunity, 106, 102308-102308 (2021)
Priyadarsani Subramanian et al.
Kidney international reports, 5(9), 1551-1557 (2020-09-22)
The majority of primary membranous nephropathy (MN) cases are no longer considered idiopathic with the discovery of the podocytic autoantigens: phospholipase A2 receptor (PLA2R) and thrombospondin type 1 domain-containing 7A (THSD7A). Limited data on PLA2R-related MN in Indians exist in...
Takamasa Iwakura et al.
PloS one, 10(9), e0138841-e0138841 (2015-09-24)
Membranous nephropathy (MN) is a leading cause of nephrotic syndrome in adults. Autoantibodies against M-type phospholipase A2 receptor (PLA2R) and thrombospondin type-1 domain-containing 7A (THSD7A), which mainly belong to the IgG4 subclass, were reported as associated antibodies for the development...